Face Transplant Surgery in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES:

• Patients aged 18–60 years with severe, unreconstructable facial disfigurement affecting >25% of the facial surface area

• Disfigurement secondary to: high-voltage electrical burns, ballistic/blast injuries (gunshot wounds), severe thermal or chemical burns, failed or maximal conventional reconstructive surgery, or massive plexiform neurofibromatosis

• Functional deficits in two or more of the following domains: oral incompetence (inability to eat/speak), nasal airway obstruction, corneal exposure due to eyelid loss, or significant midfacial skeletal destruction

• Formal psychological evaluation confirming adequate coping capacity, realistic expectations regarding motor recovery timeline, and absence of active psychosis or untreated major psychiatric disorder

• Demonstrated ability to comply with lifelong immunosuppression and follow-up protocols (critical — non-compliance is the leading cause of late rejection)

• ABO blood group compatibility with donor pool; HLA sensitization workup (Panel Reactive Antibody, PRA) — patients with PRA >80% require desensitization protocols

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• 3D CT Angiography of facial and cervical vasculature (mapping of external carotid artery branches)

• MRI Face and Neck with gadolinium contrast (soft tissue and nerve mapping)

• Electromyography (EMG) and Nerve Conduction Studies (NCS) of residual facial musculature

• Virtual Surgical Planning (VSP) with photogrammetric 3D facial surface scanning

• Full HLA typing and crossmatch; Panel Reactive Antibody (PRA) screening

• Comprehensive metabolic panel, CBC, coagulation screen (PT/INR, aPTT)

• Infectious disease screening: HIV, HBV, HCV, CMV, EBV, tuberculosis (IGRA/Quantiferon-TB Gold)

• Echocardiography (ECHO) and pulmonary function tests (PFT) for anesthetic risk stratification

• Ophthalmologic evaluation if periorbital involvement

• Formal psychiatric evaluation and neuropsychological testing

• Bone densitometry (DEXA scan) as baseline prior to corticosteroid immunosuppression

• ABSOLUTE CONTRAINDICATIONS:

• Active malignancy or history of malignancy within 5 years (due to immunosuppression-related tumor promotion risk)

• Active systemic infection or uncontrolled sepsis

• Severe cardiovascular disease (EF <35%, recent MI within 6 months)

• Severe hepatic or renal insufficiency (eGFR <30 mL/min/1.73m²) that would preclude calcineurin inhibitor use

• Active substance dependence (alcohol, opioids) without sustained remission

• Active, untreated psychosis or personality disorders incompatible with treatment adherence

• Pregnancy

• RELATIVE CONTRAINDICATIONS:

• Diabetes mellitus with end-organ damage (increases infection and wound healing risk under immunosuppression)

• Obesity (BMI >35): significantly increases perioperative complications

• Prior sensitization with PRA >80% without available desensitization protocol

SURGICAL APPROACHES IN FACIAL ALLOTRANSPLANTATION:

1. PARTIAL FACE TRANSPLANT (Zone-Specific Allotransplantation):

Indicates transfer of a specific anatomical subunit — most commonly the central face (nose, lips, chin, and associated musculature) or the lower face (mandibular zone). This approach is used when disfigurement is zone-limited and adjacent recipient tissue can serve as a vascular inflow zone. Vascular anastomoses are performed to the facial artery and vein under operative microscope (magnification ×10–25). Nerve coaptation targets the infraorbital branch (V2) of the trigeminal nerve for sensory restoration and the buccal and marginal mandibular branches of the facial nerve (CN VII) for motor restoration. Operative time: 16–22 hours.

2. FULL FACE TRANSPLANT (Total Facial Allotransplantation):

The most extensive VCA procedure, encompassing transfer of the entire facial soft tissue envelope including eyelids, nose, lips, cheeks, chin, forehead skin, and potentially underlying skeletal components (maxilla, mandible, zygoma). Bilateral vascular anastomoses are performed to the external carotid arteries and external jugular or facial veins. Motor coaptation involves the main trunk or pes anserinus of the facial nerve bilaterally. Sensory coaptation targets all three trigeminal divisions (V1, V2, V3). Operative time: 22–30+ hours. This approach has been performed in over 50 documented cases globally, including landmark cases at Brigham and Women's Hospital (Boston), Henri Mondor Hospital (Paris), and the Cleveland Clinic.

3. OSTEOMYOCUTANEOUS COMPOSITE FACE TRANSPLANT:

Includes transfer of skeletal components (typically the mid-face Le Fort III segment, maxilla, or mandibular symphysis) in addition to soft tissue. Indicated when recipient skeletal destruction precludes adequate soft tissue support. Rigid fixation is achieved with titanium plates and screws following digital pre-operative osteotomy planning via VSP software (e.g., Materialise ProPlan CMF). This variant requires additional surgical time for skeletal fixation but yields superior long-term functional and aesthetic outcomes for patients with blast or ballistic injuries.

4. IMMUNOSUPPRESSION PROTOCOLS (CRITICAL TECHNICAL DETAIL):

• Induction: Antithymocyte globulin (ATG, rabbit-derived, 1.5 mg/kg/day × 5 days) or Basiliximab (IL-2 receptor antagonist, 20 mg IV on Days 0 and 4)

• Maintenance Triple Therapy: Tacrolimus (FK506) + Mycophenolate Mofetil (MMF, 1–1.5 g twice daily) + Prednisolone (tapered to 5–10 mg/day by 6 months)

• Rejection Surveillance: Protocol skin biopsies at 1, 3, 6, 12 months using the Banff 2007 VCA classification system (Grade I–IV acute rejection)

• Emerging Protocols: Some centers are investigating minimization or withdrawal of steroids using mTOR inhibitors (sirolimus/everolimus) and co-stimulation blockade (belatacept) to reduce long-term nephrotoxicity from calcineurin inhibitors

• Opportunistic Infection Prophylaxis: Trimethoprim-sulfamethoxazole (PCP), valganciclovir (CMV prophylaxis for CMV-mismatched pairs), antifungal prophylaxis (fluconazole)

5. ADVANCED TECHNOLOGIES USED:

• Virtual Surgical Planning (VSP) and 3D-printed surgical cutting guides

• Intraoperative indocyanine green (ICG) fluorescence angiography for real-time perfusion assessment of the transplanted tissue

• Nerve monitoring with intraoperative EMG

• Hypothermic machine perfusion (HMP) for extended preservation of the donor face graft (up to 6–8 hours cold ischemia time is acceptable; machine perfusion extends this window)

• Robotic-assisted microsurgery is under investigation at select centers for suture placement in anastomosis under tremor-filtered magnification

PHASE 1 — PRE-OPERATIVE EVALUATION & LISTING (3–6 months before transplant):

• Comprehensive multidisciplinary evaluation: craniofacial surgery, transplant medicine, psychiatry, ophthalmology, speech therapy

• Completion of all diagnostic workup (3D CT angio, MRI, HLA typing, PRA, EMG/NCS, ECHO, PFTs, DEXA)

• Virtual surgical planning session: 3D photogrammetric facial scanning, VSP software modeling of recipient anatomy

• Formal listing on the national transplant registry; ABO/HLA compatibility data submitted

• Psychological counseling and informed consent process (typically multiple sessions covering realistic motor recovery expectations, immunosuppression burden, and rejection risk)

• Dental rehabilitation and oral hygiene optimization (infection risk reduction under immunosuppression)

PHASE 2 — DONOR MATCHING & PROCUREMENT (Variable — hours to months on waitlist):

• Notification of ABO-compatible brain-dead donor; urgent crossmatch and final HLA compatibility confirmation

• Simultaneous donor procurement and recipient preparation in adjacent operating rooms

• Cold ischemia time minimized; target under 4 hours (acceptable up to 6 hours with standard cold storage; HMP extends window)

• Recipient facial tissue resection performed first (skin and underlying tissue degloving) to prepare recipient vascular pedicles and nerve stumps

PHASE 3 — TRANSPLANT SURGERY (Day 0, 16–30 hours):

• General anesthesia, arterial line, central venous access, urinary catheter

• Recipient preparation: elevation of facial flap, identification and tagging of facial artery/vein bilaterally, exposure of facial nerve branches

• Allograft inset: skeletal fixation first (if osteomyocutaneous), then vascular anastomoses under operative microscope (artery first, then vein)

• Reperfusion: graft becomes pink/warm; ICG fluorescence angiography confirms perfusion

• Nerve coaptation: CN VII (motor) and trigeminal branches (sensory) using 9-0 or 10-0 nylon epineural sutures or fibrin glue-assisted coaptation

• Skin closure; wound drains placed

• Induction immunosuppression administered intraoperatively

PHASE 4 — ICU & ACUTE POST-OPERATIVE PERIOD (Days 0–14):

• ICU monitoring: hourly clinical Doppler assessment of graft perfusion (color, turgor, capillary refill, temperature probe on graft)

• Implantable Doppler probe on venous anastomosis for continuous perfusion signal monitoring

• Strict head-of-bed elevation at 30° to reduce edema

• NPO initially; nasogastric feeding tube for nutrition

• Tacrolimus trough levels checked daily; target 10–15 ng/mL in first 2 weeks

• Daily wound care; swelling peaks at Days 3–5, begins to resolve by Day 10

• Protocol skin punch biopsy at Day 7–10 (Banff grading)

• Speech therapy assessment begins (oral motor function evaluation)

PHASE 5 — STEP-DOWN WARD (Days 14–35):

• Transfer from ICU when graft perfusion is stable and patient is hemodynamically independent

• Immunosuppression fine-tuning; transition to oral tacrolimus, MMF, and prednisolone

• Initiation of structured facial rehabilitation: mirror-guided facial movement exercises, neuromuscular re-education

• Nutritional rehabilitation: transition from NG feeds to soft oral diet as oral competence allows

• Psychology and social work support sessions

• Discharge planning: patient and caregiver education on wound care, medication administration, rejection warning signs

PHASE 6 — OUTPATIENT RECOVERY IN INDIA/UAE (Weeks 5–16 before fit-to-fly):

• Weekly outpatient visits: clinical examination, Doppler assessment, blood draws (tacrolimus trough, CBC, renal function, LFTs, CMV PCR)

• Protocol skin biopsy at 3 months

• Occupational therapy and facial physiotherapy: 45–60 minutes daily

• RECOVERY MILESTONES:

• Weeks 4–6: Swelling substantially resolved; early light touch sensation in zone of sensory coaptation

• Months 3–4: Protective sensation (pain/temperature) established; voluntary lip movement may begin

• Months 6–12: Progressive voluntary facial movement (smile, brow raise); cosmetic appearance stabilizes

• Months 12–24: Maximum motor reinnervation achieved; speech intelligibility normalized

• Fit-to-fly clearance requires: stable tacrolimus levels for ≥4 weeks, no active rejection episode in prior 8 weeks, adequate patient/caregiver competency in medication management, confirmed follow-up arrangement with transplant team in home country

PHASE 7 — LONG-TERM FOLLOW-UP (Lifelong):

• Annual protocol biopsies; periodic imaging

• Lifelong immunosuppression monitoring: renal function, bone density (DEXA annually), skin cancer surveillance (annual dermatology), metabolic monitoring (HbA1c, lipids)

• Long-term risks managed: chronic rejection (intimal thickening of graft vessels), calcineurin inhibitor nephrotoxicity, post-transplant lymphoproliferative disorder (PTLD), opportunistic infections